Orthosteric neuronal nicotinic acetylcholine receptor (nAChR) antagonist (IC50
values are 0.17, 0.25, 0.4, 4.8, 6.5, 8.2, 20 and 34 μ
M at α
3 and α
3 receptors respectively). Attenuates nicotine-evoked dopamine release from the ventral tegmental area in vivo
= 0.2 nM) and reduces nicotine self-administration in rats. Brain penetrant.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
N,N'alkane-diyl-bis-3-picoliniums as nicotinic receptor antagonists: Inhibition of nicotine-evoked dopamine release and hyperactivity.
Dwoskin et al.
Region-specific effects of the N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide on nicotine-induced increase in extracellular dopamine in vivo.
Rahman et al.
Bis-azaaromatic quaternary ammonium analogues: ligands for α4β2* and β7* subtypes of neuronal nicotinic receptors
Ayers et al.
The citations listed below are publications that use Tocris products. Selected citations for bPiDDB include:
Showing Results 1 - 1 of 1